Pentoxifylline affects cytokine reaction in cardiopulmonary bypass

Simple item page
dc.contributor.authorIskesen, I
dc.contributor.authorSaribulbul, O
dc.contributor.authorCerrahoglu, M
dc.contributor.authorOnur, E
dc.contributor.authorDestan, B
dc.contributor.authorSirin, BH
dc.date.accessioned2024-07-18T11:48:49Z
dc.date.available2024-07-18T11:48:49Z
dc.description.abstractBackground. Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations. Methods. In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points. Results. TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05). Conclusions. Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.
dc.identifier.issn1098-3511
dc.identifier.other1522-6662
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/3541
dc.language.isoEnglish
dc.publisherFORUM MULTIMEDIA PUBLISHING, LLC
dc.subjectSYSTEMIC INFLAMMATORY RESPONSE
dc.subjectCARDIAC-SURGERY
dc.subjectLUNG INJURY
dc.subjectMECHANISMS
dc.subjectAPROTININ
dc.subjectHEART
dc.titlePentoxifylline affects cytokine reaction in cardiopulmonary bypass
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu